140 related articles for article (PubMed ID: 3193189)
1. Prognostic implications of the proliferative potential of low-grade astrocytomas.
Hoshino T; Rodriguez LA; Cho KG; Lee KS; Wilson CB; Edwards MS; Levin VA; Davis RL
J Neurosurg; 1988 Dec; 69(6):839-42. PubMed ID: 3193189
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
4. Proliferative potential and prognostic evaluation of low-grade astrocytomas.
Ito S; Chandler KL; Prados MD; Lamborn K; Wynne J; Malec MK; Wilson CB; Davis RL; Hoshino T
J Neurooncol; 1994; 19(1):1-9. PubMed ID: 7815099
[TBL] [Abstract][Full Text] [Related]
5. Variability in the proliferative potential of human gliomas.
Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
[TBL] [Abstract][Full Text] [Related]
6. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
7. Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients.
Lamborn KR; Prados MD; Kaplan SB; Davis RL
Cancer; 1999 Feb; 85(4):925-35. PubMed ID: 10091772
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
[TBL] [Abstract][Full Text] [Related]
9. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
10. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults.
Fujimaki T; Matsutani M; Nakamura O; Asai A; Funada N; Koike M; Segawa H; Aritake K; Fukushima T; Houjo S
Cancer; 1991 Mar; 67(6):1629-34. PubMed ID: 2001552
[TBL] [Abstract][Full Text] [Related]
11. Histological grading and bromodeoxyuridine labeling index of astrocytomas. Comparative study in a series of 60 cases.
Labrousse F; Daumas-Duport C; Batorski L; Hoshino T
J Neurosurg; 1991 Aug; 75(2):202-5. PubMed ID: 1649271
[TBL] [Abstract][Full Text] [Related]
12. Correlation of in vitro bromodeoxyuridine labeling index and DNA aneuploidy with survival or recurrence in brain-tumor patients.
Nishizaki T; Orita T; Kajiwara K; Ikeda N; Ohshita N; Nakayama H; Furutani Y; Ikeyama Y; Akimura T; Kamiryo T
J Neurosurg; 1990 Sep; 73(3):396-400. PubMed ID: 1696625
[TBL] [Abstract][Full Text] [Related]
13. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
14. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
[TBL] [Abstract][Full Text] [Related]
15. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bromodeoxyuridine labeling indices obtained from tissue sections and flow cytometry of brain tumors.
Nagashima T; Hoshino T; Cho KG; Senegor M; Waldman F; Nomura K
J Neurosurg; 1988 Mar; 68(3):388-92. PubMed ID: 3278075
[TBL] [Abstract][Full Text] [Related]
17. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
18. Proliferative potential of brain metastases.
Cho KG; Hoshino T; Pitts LH; Nomura K; Shimosato Y
Cancer; 1988 Aug; 62(3):512-5. PubMed ID: 3390791
[TBL] [Abstract][Full Text] [Related]
19. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
